PSU Profiles
Keywords
Last Name
Institution

Xuemei Huang

TitleProfessor
InstitutionCollege of Medicine
DepartmentNeurology
Address500 University Drive Hershey PA 17033
Phone7175311803

 Overview 
 overview
PREFERRED TITLE/ROLE:



Physician, Associate Professor

Vice Chair for Research



EDUCATION:



Fellowship, Neurology Research, University of North Carolina School of Medicine (2002)

Fellowship, Movement Disorders, Emory University Medical Center (Georgia) (2001)

Residency, Neurology, University of North Carolina School of Medicine (2000)

Internship, Medicine, University of Washington School of Medicine (1997)

M.D., Beijing Medical University (1987)






 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Park J, Jo HJ, Lewis MM, Huang X, Latash ML. Effects of Parkinson's disease on optimization and structure of variance in multi-finger tasks. Exp Brain Res. 2013 Nov; 231(1):51-63.
    View in: PubMed
  2. Lee EY, Sen S, Eslinger PJ, Wagner D, Shaffer ML, Kong L, Lewis MM, Du G, Huang X. Early cortical gray matter loss and cognitive correlates in non-demented Parkinson's patients. Parkinsonism Relat Disord. 2013 Dec; 19(12):1088-93.
    View in: PubMed
  3. Sterling NW, Du G, Lewis MM, Dimaio C, Kong L, Eslinger PJ, Styner M, Huang X. Striatal shape in Parkinson's disease. Neurobiol Aging. 2013 Nov; 34(11):2510-6.
    View in: PubMed
  4. Lewis MM, Galley S, Johnson S, Stevenson J, Huang X, McKeown MJ. The role of the cerebellum in the pathophysiology of Parkinson's disease. Can J Neurol Sci. 2013 May; 40(3):299-306.
    View in: PubMed
  5. Park J, Lewis MM, Huang X, Latash ML. Effects of olivo-ponto-cerebellar atrophy (OPCA) on finger interaction and coordination. Clin Neurophysiol. 2013 May; 124(5):991-8.
    View in: PubMed
  6. Lewis MM, Du G, Kidacki M, Patel N, Shaffer ML, Mailman RB, Huang X. Higher iron in the red nucleus marks Parkinson's dyskinesia. Neurobiol Aging. 2013 May; 34(5):1497-503.
    View in: PubMed
  7. Du G, Lewis MM, Sen S, Wang J, Shaffer ML, Styner M, Yang QX, Huang X. Imaging nigral pathology and clinical progression in Parkinson's disease. Mov Disord. 2012 Nov; 27(13):1636-43.
    View in: PubMed
  8. Park J, Wu YH, Lewis MM, Huang X, Latash ML. Changes in multifinger interaction and coordination in Parkinson's disease. J Neurophysiol. 2012 Aug 1; 108(3):915-24.
    View in: PubMed
  9. Du G, Lewis MM, Shaffer ML, Chen H, Yang QX, Mailman RB, Huang X. Serum cholesterol and nigrostriatal R2* values in Parkinson's disease. PLoS One. 2012; 7(4):e35397.
    View in: PubMed
  10. Huang X, Mahoney JM, Lewis MM. Both coordination and symmetry of arm swing are reduced in Parkinson's disease. Gait Posture. 2012 Mar; 35(3):373-7.
    View in: PubMed
  11. Gao J, Huang X, Park Y, Hollenbeck A, Chen H. An exploratory study on CLU, CR1 and PICALM and Parkinson disease. PLoS One. 2011; 6(8):e24211.
    View in: PubMed
  12. Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, Mailman R, Chen H. Serum cholesterol and the progression of Parkinson's disease: results from DATATOP. PLoS One. 2011; 6(8):e22854.
    View in: PubMed
  13. Gao J, Huang X, Park Y, Liu R, Hollenbeck A, Schatzkin A, Mailman RB, Chen H. Apolipoprotein E genotypes and the risk of Parkinson disease. Neurobiol Aging. 2011 Nov; 32(11):2106.e1-6.
    View in: PubMed
  14. Du G, Lewis MM, Styner M, Shaffer ML, Sen S, Yang QX, Huang X. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord. 2011 Aug 1; 26(9):1627-32.
    View in: PubMed
  15. Gao J, Huang X, Park Y, Hollenbeck A, Blair A, Schatzkin A, Chen H. Daytime napping, nighttime sleeping, and Parkinson disease. Am J Epidemiol. 2011 May 1; 173(9):1032-8.
    View in: PubMed
  16. Lewis MM, Du G, Sen S, Kawaguchi A, Truong Y, Lee S, Mailman RB, Huang X. Differential involvement of striato- and cerebello-thalamo-cortical pathways in tremor- and akinetic/rigid-predominant Parkinson's disease. Neuroscience. 2011 Mar 17; 177:230-9.
    View in: PubMed
  17. Brenner SR, Chen H, Kamel F, Park Y, Hollenbeck A, Huang X. Smoking duration, intensity, and risk of Parkinson disease. Neurology. 2010 Aug 10; 75(6):574-5; author reply 574.
    View in: PubMed
  18. Xu Q, Park Y, Huang X, Hollenbeck A, Blair A, Schatzkin A, Chen H. Physical activities and future risk of Parkinson disease. Neurology. 2010 Jul 27; 75(4):341-8.
    View in: PubMed
  19. Chen H, Huang X, Guo X, Mailman RB, Park Y, Kamel F, Umbach DM, Xu Q, Hollenbeck A, Schatzkin A, Blair A. Smoking duration, intensity, and risk of Parkinson disease. Neurology. 2010 Mar 16; 74(11):878-84.
    View in: PubMed
  20. Huang X, Chen H, Petrovitch H, Mailman R, Ross W. Reply: Plasma cholesterol and Parkinson's disease: Is the puzzle only apparent? Mov Disord. 2010 Jan 15; 25(1):137.
    View in: PubMed
  21. Sen S, Kawaguchi A, Truong Y, Lewis MM, Huang X. Dynamic changes in cerebello-thalamo-cortical motor circuitry during progression of Parkinson's disease. Neuroscience. 2010 Mar 17; 166(2):712-9.
    View in: PubMed
  22. Lewis MM, Smith AB, Styner M, Gu H, Poole R, Zhu H, Li Y, Barbero X, Gouttard S, McKeown MJ, Mailman RB, Huang X. Asymmetrical lateral ventricular enlargement in Parkinson's disease. Eur J Neurol. 2009 Apr; 16(4):475-81.
    View in: PubMed
  23. Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW. Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study. Mov Disord. 2008 May 15; 23(7):1013-8.
    View in: PubMed
  24. McKeown MJ, Uthama A, Abugharbieh R, Palmer S, Lewis M, Huang X. Shape (but not volume) changes in the thalami in Parkinson disease. BMC Neurol. 2008; 8:8.
    View in: PubMed
  25. Huang X, Lee YZ, McKeown M, Gerig G, Gu H, Lin W, Lewis MM, Ford S, Tröster AI, Weinberger DR, Styner M. Asymmetrical ventricular enlargement in Parkinson's disease. Mov Disord. 2007 Aug 15; 22(11):1657-60.
    View in: PubMed
  26. McKeown MJ, Li J, Huang X, Lewis MM, Rhee S, Young Truong KN, Wang ZJ. Local linear discriminant analysis (LLDA) for group and region of interest (ROI)-based fMRI analysis. Neuroimage. 2007 Sep 1; 37(3):855-65.
    View in: PubMed
  27. Lewis MM, Slagle CG, Smith AB, Truong Y, Bai P, McKeown MJ, Mailman RB, Belger A, Huang X. Task specific influences of Parkinson's disease on the striato-thalamo-cortical and cerebello-thalamo-cortical motor circuitries. Neuroscience. 2007 Jun 15; 147(1):224-35.
    View in: PubMed
  28. George MS, Molnar CE, Grenesko EL, Anderson B, Mu Q, Johnson K, Nahas Z, Knable M, Fernandes P, Juncos J, Huang X, Nichols DE, Mailman RB. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res. 2007 Jul; 93(1-3):42-50.
    View in: PubMed
  29. Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, Xiang D, Murrow RW, Wang YZ, Poole C. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord. 2007 Feb 15; 22(3):377-81.
    View in: PubMed
  30. Mailman RB, Huang X. Dopamine receptor pharmacology. Handb Clin Neurol. 2007; 83:77-105.
    View in: PubMed
  31. Lewis MM, Huang X, Nichols DE, Mailman RB. D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease. CNS Neurol Disord Drug Targets. 2006 Jun; 5(3):345-53.
    View in: PubMed
  32. Huang X, Chen P, Kaufer DI, Tröster AI, Poole C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol. 2006 Feb; 63(2):189-93.
    View in: PubMed
  33. Huang X, Chen PC, Poole C. APOE-[epsilon]2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology. 2004 Jun 22; 62(12):2198-202.
    View in: PubMed
  34. Mailman R, Huang X, Nichols DE. Parkinson's disease and D1 dopamine receptors. Curr Opin Investig Drugs. 2001 Nov; 2(11):1582-91.
    View in: PubMed
  35. Huang X, Lawler CP, Lewis MM, Nichols DE, Mailman RB. D1 dopamine receptors. Int Rev Neurobiol. 2001; 48:65-139.
    View in: PubMed
  36. Cozzi NV, Frescas S, Marona-Lewicka D, Huang X, Nichols DE. Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential. Pharmacol Biochem Behav. 1998 Mar; 59(3):709-15.
    View in: PubMed
  37. Nichols DE, Monte A, Huang X, Marona-Lewicka D. Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Behav Brain Res. 1996; 73(1-2):117-9.
    View in: PubMed
  38. Oberlender R, Ramachandran PV, Johnson MP, Huang X, Nichols DE. Effect of a chiral 4-alkyl substituent in hallucinogenic amphetamines. J Med Chem. 1995 Sep 1; 38(18):3593-601.
    View in: PubMed
  39. Nichols DE, Frescas S, Marona-Lewicka D, Huang X, Roth BL, Gudelsky GA, Nash JF. 1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist. J Med Chem. 1994 Dec 9; 37(25):4346-51.
    View in: PubMed
  40. Huang X, Marona-Lewicka D, Pfaff RC, Nichols DE. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives. Pharmacol Biochem Behav. 1994 Mar; 47(3):667-73.
    View in: PubMed
  41. Pfaff RC, Huang X, Marona-Lewicka D, Oberlender R, Nichols DE. Lysergamides revisited. NIDA Res Monogr. 1994; 146:52-73.
    View in: PubMed
  42. Sprague JE, Huang X, Kanthasamy A, Nichols DE. Attenuation of 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan. Life Sci. 1994; 55(15):1193-8.
    View in: PubMed
  43. Huang X, Nichols DE. 5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. Eur J Pharmacol. 1993 Jul 20; 238(2-3):291-6.
    View in: PubMed
  44. Nichols DE, Marona-Lewicka D, Huang X, Johnson MP. Novel serotonergic agents. Drug Des Discov. 1993; 9(3-4):299-312.
    View in: PubMed
  45. Huang X, Marona-Lewicka D, Nichols DE. p-methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur J Pharmacol. 1992 Dec 8; 229(1):31-8.
    View in: PubMed
  46. Tomaszewski Z, Johnson MP, Huang X, Nichols DE. Benzofuran bioisosteres of hallucinogenic tryptamines. J Med Chem. 1992 May 29; 35(11):2061-4.
    View in: PubMed
  47. Oberlender R, Pfaff RC, Johnson MP, Huang XM, Nichols DE. Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-aminobutane. J Med Chem. 1992 Jan 24; 35(2):203-11.
    View in: PubMed
  48. Johnson MP, Huang XM, Nichols DE. Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue. Pharmacol Biochem Behav. 1991 Dec; 40(4):915-22.
    View in: PubMed
  49. Huang XM, Johnson MP, Nichols DE. Reduction in brain serotonin markers by alpha-ethyltryptamine (Monase). Eur J Pharmacol. 1991 Jul 23; 200(1):187-90.
    View in: PubMed
  50. Nichols DE, Snyder SE, Oberlender R, Johnson MP, Huang XM. 2,3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines. J Med Chem. 1991 Jan; 34(1):276-81.
    View in: PubMed
  51. Johnson MP, Huang XM, Oberlender R, Nash JF, Nichols DE. Behavioral, biochemical and neurotoxicological actions of the alpha-ethyl homologue of p-chloroamphetamine. Eur J Pharmacol. 1990 Nov 20; 191(1):1-10.
    View in: PubMed
Huang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_